BioTechUSA Group’s revenue increased, EBITDA decreased in 2025

By: Trademagazin Date: 2026. 03. 17. 11:41

🎧 Hallgasd a cikket: Nyelv: Sebesség: 1.05×

The net sales revenue of the BioTechUSA group increased to 100.9 billion forints in 2025 from 93.7 billion forints in the previous year, while its earnings before interest, taxes, depreciation and amortization (EBITDA) decreased from 10.7 to 5.48 billion forints due to persistently high raw material prices.

According to the company, the market for dietary supplements and specialty foods was strongly influenced by geopolitical conflicts, volatility in energy prices, and difficulties in raw material supply last year. The BioTechUSA group of companies, which employs almost 2,000 people, has maintained its operational stability and market positions in this environment: it is present in 104 countries, operates 51 webshops, has 332 physical stores in Europe and works with more than 4,800 business partners worldwide.

The announcement quoted Bálint Lévai, the owner of the BioTechUSA group of companies, as explaining that last year the market for dietary supplements and specialty foods continued to be determined by the narrow supply of protein sources. It was a conscious decision that the increased raw material prices were only partially reflected in consumer prices, so the record sales revenue was coupled with decreasing profitability.

The information highlighted that the export activity of the company group is decisive, with almost 80 billion forints sold abroad. Last year, infrastructure developments worth 9 billion forints in recent years were completed – including automated logistics solutions, energy investments and the shaker logo plant – which provide the basis for increasing efficiency in the next period.

The BioTechUSA group of companies is counting on a more favorable business and industry environment for 2026. With the return on investments from previous years, the full utilization of automated systems and new production capacities, the company’s medium-term goal is to achieve a growth trajectory of around 10 percent even on a higher base. The long-term strategy continues to prioritize sustainable development, innovation and further strengthening in international markets in the dynamically changing dietary supplement and specialty food market, the statement said.